OPTOLANE Technologies

What OPTOLANE Technologies does

OPTOLANE Technologies Inc is a South Korean in-vitro diagnostics company founded in December 2012, headquartered in Yongin, Gyeonggi-do, with 51–100 employees. The company develops a proprietary semiconductor-based molecular diagnostic platform that integrates CMOS sensor technology with Digital Real-Time PCR (drPCR), combining fluorescence detection and thermal control directly on a chip across approximately 20,000 nano-well partitions. This architecture enables a compact (~3.2 kg) instrument with 1–1.5 hour turnaround time and absolute quantification without standard curves, compared with conventional digital PCR systems that typically exceed 4 hours and 30 kg.

The product portfolio is anchored by the LOAA Analyzer platform — both the single-module On-Point and the scalable LOAA-M (1 console + 1–4 modules, up to 16 simultaneous tests) — and a consumable kit catalog organized into three vertical brands: Dr. PCR/Genotizer for hematology and oncology (BCR-ABL1 for CML monitoring with MR 6.34 sensitivity, HER2 CNV for breast cancer), Kaira and Genoplexor for infectious disease (SARS-CoV-2, Monkeypox, Malaria, Arboviruses, Eczema/Vesicular panels, Avian Influenza), and Genoplexor veterinary kits (FMDV, AIV, Bee Pathogens, PRRSV/PCV2, Rabies). Software includes LOAA On-Point Pro for result analysis and a Closed Network Solution supporting up to 200 networked instruments.

The business model is a classic razor-and-blade hardware-plus-consumables structure, sold direct B2B to hospitals, clinical and veterinary diagnostic laboratories, and life science research institutions across Korea, the US (FDA listed/EUA), Europe (CE-IVD), Brazil (ANVISA), and Japan (MDSAP). The company has raised approximately KRW 86–104 billion across Series A through Series D+1 (2015–2024) and was awarded the $10 Million Export Tower in December 2022. Revenue is not publicly disclosed and the company remains privately held.

Name

OPTOLANE Technologies

Legal name

OPTOLANE Technologies Inc

Website

https://optolane.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

51–100 employees

Short description

OPTOLANE Technologies is a South Korean in-vitro diagnostics company that develops semiconductor-based Digital Real-Time PCR (drPCR) platforms and multiplex molecular diagnostic kits for hospitals, veterinary laboratories, and life science research institutions worldwide.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics / In-Vitro Diagnostic PCR Systems

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)

akta.pro secondary industry

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)

Keywords

• Digital PCR systems
• Molecular diagnostics
• In vitro diagnostics
• Veterinary diagnostic kits
• Infectious disease detection

Headquarters

HQ city

Seongnam

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. PCR Instruments and Analyzers: Sale of LOAA Analyzer and LOAA-M diagnostic instruments - in vitro diagnostic medical devices used to amplify and detect specific genes (DNA or RNA). Instruments are sold directly to healthcare providers, diagnostic laboratories, and research institutions.
2. PCR Consumables and Reagents: Sale of proprietary PCR cartridges, detection kits, and reagents including Dr. PCR BCR-ABL1 Major IS Detection Kit, Genotizer HDR kits, Kaira infectious disease detection kits, Genoplexor multiplex panels, and associated primer/probe mixtures and controls.
3. Software Licenses: LOAA On-Point Pro software for integrated analysis of test results, project management, and data visualization (scatter charts, ratio, event, list views).

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

OPTOLANE Technologies designs, manufactures, and sells semiconductor-based in-vitro diagnostic instruments (LOAA Analyzer On-Point and LOAA-M systems) and proprietary cartridge-based PCR reagent kits for oncology, infectious disease, veterinary, and life science research applications. Its proprietary platform integrates CMOS sensor technology with digital real-time PCR, using ~20,000 nano-well partitions to enable compact, high-sensitivity molecular diagnostics sold to professional healthcare and research buyers.

Product overview

OPTOLANE Technologies is a semiconductor-based in vitro diagnostic company specializing in Digital Real-Time PCR systems that combine real-time PCR and digital PCR capabilities. The product portfolio consists of the LOAA Analyzer platform (LOAA-M and On-Point models) as core instruments, supported by Genoplexor multiplex real-time PCR kits (for human infectious diseases like Malaria, Arbovirus, and veterinary applications like FMDV, AIV, Bee Pathogens), Dr. PCR digital real-time PCR kits (for oncology applications like BCR-ABL1 monitoring), and Kaira rapid detection kits. The technology is built on proprietary CMOS semiconductor sensor integration with MEMS technology, enabling compact instruments (~3.2 kg) with fast turnaround times (30 minutes to 1.5 hours). OPTOLANE also provides software solutions including LOAA On-Point Pro for result analysis and Closed Network Solution for managing multiple instruments.

Differentiator

Problem solved

Functional benefit

Brands

• Genoplexor: Multiple Real-Time PCR technology platform that supports diagnosis of up to 16 targets simultaneously with one of the shortest turnaround times in the world.
• Genotizer
• Dr. PCR
• Kaira
• LOAA

Products and services

• LOAA Analyzer (On-Point)

Quantifiable outcome

• Detection sensitivity up to MR 6.34 (0.00005% IS) for BCR-ABL1 quantification in CML patients
• +4 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability3 records

Feature5 records

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds10 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OPTOLANE Technologies